A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  Berg, Jolene K ^a   Kim, Eric H ^b   Li, Benjamin ^b   Joelsson, Bo ^b   Youssef, Nader N ^b  

^a DAVITA CLINICAL RESEARCH   (United States)

^b NPS Pharmaceuticals   (United States)

Author keywords

Gastric emptying; Pharmacodynamics; Pharmacokinetics; Teduglutide

Indexed keywords

ABSORPTION; ACETAMINOPHEN; ADULT; AREA UNDER CURVE; DOUBLE-BLIND METHOD; FEMALE; GASTRIC EMPTYING; GASTROINTESTINAL AGENTS; HUMANS; MALE; PEPTIDES; YOUNG ADULT;

EID: 84893667656     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-14-25     Document Type: Article

References (57)

1. Drucker DJ, Asa S. Glucagon gene expression in vertebrate brain. J Biol Chem 1988, 263(27):13475-13478.
2. Drucker DJ, Brubaker PL. Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine. Proc Natl Acad Sci USA 1989, 86(11):3953-3957. 10.1073/pnas.86.11.3953, 287366, 2542959.
3. Baggio LL, Drucker DJ. Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2. Best Pract Res Clin Endocrinol Metab 2004, 18(4):531-554. 10.1016/j.beem.2004.08.001, 15533774.
4. Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 1986, 119(4):1467-1475. 10.1210/endo-119-4-1467, 3530719.
5. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993, 138(1):159-166. 10.1677/joe.0.1380159, 7852887.
6. Xiao Q, Boushey RP, Drucker DJ, Brubaker PL. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 1999, 117(1):99-105. 10.1016/S0016-5085(99)70555-X, 10381915.
7. Anvari M, Paterson CA, Daniel EE, McDonald TJ. Effects of GLP-1 on gastric emptying, antropyloric motility, and transpyloric flow in response to a nonnutrient liquid. Dig Dis Sci 1998, 43(6):1133-1140. 10.1023/A:1018863716749, 9635598.
8. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997, 273(4 Pt 1):G920-927.
9. Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 1998, 68(3):525-530.
10. Rotondo A, Amato A, Lentini L, Baldassano S, Mule F. Glucagon-like peptide-1 relaxes gastric antrum through nitric oxide in mice. Peptides 2011, 32(1):60-64. 10.1016/j.peptides.2010.09.028, 20933560.
11. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstrom PM. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 1998, 43(10):2284-2290. 10.1023/A:1026678925120, 9790467.
12. Wettergren A, Wojdemann M, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide. Peptides 1998, 19(5):877-882. 10.1016/S0196-9781(98)00020-5, 9663453.
13. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992, 130(1):159-166.
14. Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988, 123(4):2009-2013. 10.1210/endo-123-4-2009, 2901341.
15. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987, 2(8571):1300-1304.
16. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996, 93(15):7911-7916. 10.1073/pnas.93.15.7911, 38848, 8755576.
17. Tsai CH, Hill M, Asa SL, Brubaker PL, Drucker DJ. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol Endocrinol Metab 1997, 273:E77-84.
18. Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 2000, 47(1):112-119. 10.1136/gut.47.1.112, 1727982, 10861272.
19. Kato Y, Yu D, Schwartz MZ. Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo. J Pediatr Surg 1999, 34(1):18-20. discussion 20-11, 10.1016/S0022-3468(99)90221-X, 10022136.
20. Sorensen LB, Flint A, Raben A, Hartmann B, Holst JJ, Astrup A. No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes Relat Metab Disord 2003, 27(4):450-456. 10.1038/sj.ijo.0802247, 12664078.
21. Meier JJ, Nauck MA, Pott A, Heinze K, Goetze O, Bulut K, Schmidt WE, Gallwitz B, Holst JJ. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006, 130(1):44-54. 10.1053/j.gastro.2005.10.004, 16401467.
22. Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985, 28(9):704-707. 10.1007/BF00291980, 3905480.
23. Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism 1994, 43(1):104-108. 10.1016/0026-0495(94)90164-3, 8289665.
24. Jonderko G, Jonderko K, Golab T. Effect of glucagon on gastric emptying and on postprandial gastrin and insulin release in man. Mater Med Pol 1989, 21(2):92-96.
25. Mochiki E, Suzuki H, Takenoshita S, Nagamachi Y, Kuwano H, Mizumoto A, Itoh Z. Mechanism of inhibitory effect of glucagon on gastrointestinal motility and cause of side effects of glucagon. J Gastroenterol 1998, 33(6):835-841. 10.1007/s005350050184, 9853556.
26. Wojdemann M, Wettergren A, Hartmann B, Holst JJ. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998, 33(8):828-832. 10.1080/00365529850171486, 9754730.
27. Amato A, Baldassano S, Serio R, Mule F. Glucagon-like peptide-2 relaxes mouse stomach through vasoactive intestinal peptide release. Am J Physiol Gastrointest Liver Physiol 2009, 296(3):G678-684. 10.1152/ajpgi.90587.2008, 19109404.
28. Schmidt PT, Naslund E, Gryback P, Jacobsson H, Hartmann B, Holst JJ, Hellstrom PM. Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul Pept 2003, 116(1-3):21-25.
29. Nagell CF, Wettergren A, Pedersen JF, Mortensen D, Holst JJ. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scand J Gastroenterol 2004, 39(4):353-358. 10.1080/00365520410004424, 15125467.
30. Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001, 120(4):806-815. 10.1053/gast.2001.22555, 11231933.
31. Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 2011, 60(7):902-914. 10.1136/gut.2010.218271, 3112364, 21317170.
32. Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, Ziegler TR, Gregory J, Tappenden KA, Holst J, Mortensen PB. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005, 54(9):1224-1231. 10.1136/gut.2004.061440, 1774653, 16099790.
33. Hollwarth ME. Short bowel syndrome: pathophysiological and clinical aspects. Pathophysiology 1999, 6:1-19.
34. O'Keefe SJ, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, Shaffer J. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol 2006, 4(1):6-10. 10.1016/j.cgh.2005.10.002, 16431298.
35. Tappenden K, Edelman J. Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, enhances the structure of the small intestinal mucosa in parenteral support-dependent short bowel syndrome-intestinal failure (SBS-IF) subjects without inducing dysplasia. Am J Gastroenterol 2011, 106:S98.
36. Jeppesen PB, Pertkiewicz M, Seidner DL, O'Keefe S, Heinze H, Joelsson B. Teduglutide, a novel analogue of glucagon-like peptide 2 (GLP-2), is effective and safe in reducing parenteral support volume in short bowel syndrome-intestinal failure subjects: results from a 24-week, placebo-controlled phase 3 trial (STEPS). Gastroenterology 2011, 140(5 Suppl 1):S146.
37. Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper S, Brubaker PL. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 1997, 15(7):673-677. 10.1038/nbt0797-673, 9219272.
38. Tavares W, Drucker DJ, Brubaker PL. Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab 2000, 278(1):E134-139.
39. Marier JF, Beliveau M, Mouksassi MS, Shaw P, Cyran J, Kesavan J, Wallens J, Zahir H, Wells D, Caminis J. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol 2008, 48(11):1289-1299. 10.1177/0091270008320605, 18974283.
40. Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, Holst JJ, Christiansen C. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 2009, 45(5):833-842. 10.1016/j.bone.2009.07.008, 19631303.
41. Kimura T, Higaki K. Gastrointestinal transit and drug absorption. Biol Pharm Bull 2002, 25(2):149-164. 10.1248/bpb.25.149, 11853157.
42. Clements JA, Heading RC, Nimmo WS, Prescott LF. Kinetics of acetaminophen absorption and gastric emptying in man. Clin Pharmacol Ther 1978, 24(4):420-431.
43. Lien HC, Chen GH, Chang CS, Kao CH, Wang SJ. The effect of coffee on gastric emptying. Nucl Med Commun 1995, 16(11):923-926. 10.1097/00006231-199511000-00008, 8587758.
44. Miners JO, Attwood J, Birkett DJ. Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br J Clin Pharmacol 1983, 16(5):503-509. 10.1111/j.1365-2125.1983.tb02207.x, 1428054, 6416284.
45. Nightingale JM, Kamm MA, van der Sijp JR, Morris GP, Walker ER, Mather SJ, Britton KE, Lennard-Jones JE. Disturbed gastric emptying in the short bowel syndrome. Evidence for a 'colonic brake'. Gut 1993, 34(9):1171-1176. 10.1136/gut.34.9.1171, 1375448, 8406148.
46. Jeppesen PB, Hartmann B, Hansen BS, Thulesen J, Holst JJ, Mortensen PB. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut 1999, 45(4):559-563. 10.1136/gut.45.4.559, 1727702, 10486365.
47. Jian R, Vigneron N, Najean Y, Bernier JJ. Gastric emptying and intragastric distribution of lipids in man. A new scintigraphic method of study. Dig Dis Sci 1982, 27(8):705-711. 10.1007/BF01393765, 7094791.
48. Cortot A, Phillips SF, Malagelada JR. Gastric emptying of lipids after ingestion of a solid-liquid meal in humans. Gastroenterology 1981, 80(5 pt 1):922-927.
49. Cortot A, Phillips SF, Malagelada JR. Gastric emptying of lipids after ingestion of an homogenized meal. Gastroenterology 1979, 76(5 Pt 1):939-944.
50. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011, 60(5):1561-1565. 10.2337/db10-0474, 3292331, 21430088.
51. O'Keefe SJ, Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel syndrome-intestinal failure. Clin Gastroenterol Hepatol 2013, 11(7):815-823. 10.1016/j.cgh.2012.12.029, 23333663.
52. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003, 88(7):3082-3089. 10.1210/jc.2002-021545, 12843147.
53. Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, DeFronzo RA, Cersosimo E. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2008, 294(5):E846-852. 10.1152/ajpendo.00030.2008, 18334612.
54. Dupre J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 2004, 89(7):3469-3473. 10.1210/jc.2003-032001, 15240633.
55. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001, 281(1):E155-161.
56. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005, 62(2):173-181.
57. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008, 24(10):2943-2952. 10.1185/03007990802418851, 18786299.